Anti-GPR135 (aa 391-493) polyclonal antibody

Previous studies have revealed a robust association between exposure to asbestos and human lung cancer. Accumulating evidence has highlighted the role of epigenome deregulation in the mechanism of carcinogen-induced malignancies. We examined the impact of asbestos on DNA methylation. Our genome-wide studies (using Illumina HumanMethylation450K BeadChip) of lung cancer tissue and paired normal lung from 28 asbestos-exposed or non-exposed patients, mostly smokers, revealed distinctive DNA methylation changes. We identified a number of differentially methylated regions (DMR) and differentially variable, differentially methylated CpGs (DVMC), with individual CpGs further validated by pyrosequencing in an independent series of 91 non-small cell lung cancer and paired normal lung. We discovered and validated BEND4, ZSCAN31 and GPR135 as significantly hypermethylated in lung cancer. DMRs in genes such as RARB (FDR 1.1 x 10(-19), mean change in beta [angstrom] -0.09), GPR135 (FDR 1.87 x 10(-8), mean -0.09) and TPO (FDR 8.58 x 10(-5), mean angstrom -0.11), and DVMCs in NPTN, NRG2, GLT25D2 and TRPC3 (all with p <0.05, t-test) were significantly associated with asbestos exposure status in exposed versus non-exposed lung tumors. Hypomethylation was characteristic to DVMCs in lung cancer tissue from asbestos-exposed subjects. When DVMCs related to asbestos or smoking were analyzed, 96% of the elements were unique to either of the exposures, consistent with the concept that the methylation changes in tumors may be specific for risk factors. In conclusion, we identified novel DNA methylation changes associated with lung tumors and asbestos exposure, suggesting that changes may be present in causal pathway from asbestos exposure to lung cancer.

G-protein-coupled receptors (GPCRs) are important mediators of signal transduction and targets for pharmacological therapeutics. Novel receptor-ligand systems have been discovered through the identification and analysis of orphan GPCRs (oGPCRs). Here we describe the discovery of seven novel human genes encoding oGPCRs. Each novel oGPCR gene was discovered using customized searches of the GenBank genomic databases with previously known GPCR-encoding sequences. The expressed genes can now be used in assays to determine endogenous and pharmacological ligands. GPR133, GPR134, GPR135, GPR136, and GPR137 share identities with a prostate-specific odorant-like GPCR-encoding gene (PSGR). GPR138 and GPR139 share identities with an odorant-like gene derived from human erythroid cells. Transcripts encoding GPR133, GPR134, GPR135, GPR136, and GPR137 were detected in various CNS tissues. The expression of odorant-like genes in non-olfactory tissues requires further clarification, which may be achieved through the search for endogenous cognate ligands for these and other oGPCRs. (C) 2003 Elsevier Science (USA). All rights reserved.